Format

Send to

Choose Destination
See comment in PubMed Commons below
Vascul Pharmacol. 2014 Jan;60(1):42-8. doi: 10.1016/j.vph.2013.11.004. Epub 2013 Dec 5.

Low density lipoprotein induces upregulation of vasoconstrictive endothelin type B receptor expression.

Author information

1
Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, China; Division of Experimental Vascular Research, Institute of Clinical Science in Lund, Lund University, Lund, Sweden. Electronic address: cangbaoxu@yahoo.com.
2
Division of Experimental Vascular Research, Institute of Clinical Science in Lund, Lund University, Lund, Sweden.
3
Laboratory Animal Center, Xi'an Jiaotong University School of Medicine, Xi'an, China.
4
Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, China; Division of Experimental Vascular Research, Institute of Clinical Science in Lund, Lund University, Lund, Sweden.

Abstract

Vasoconstrictive endothelin type B (ET(B)) receptors promote vasospasm and ischemic cerebro- and cardiovascular diseases. The present study was designed to examine if low density lipoprotein (LDL) induces upregulation of vasoconstrictive ET(B) receptor expression and if extracellular signal-regulated kinases 1 and 2 (ERK1/2) and p38 mitogen-activated protein kinase (MAPK) signal pathways are involved in this process. Rat mesenteric artery segments were organ cultured in the presence and absence of LDL with or without inhibitors for MAPK kinase 1 and 2 (MEK1/2), p38 and transcription. The upregulation of vasoconstrictive ET(B) receptor expression was studied using a sensitive myograph, real-time PCR and Western blot. LDL (11, 22 and 44 mg protein/L) concentration-dependently induced upregulation of vasoconstrictive ETB receptor expression with increase in the receptor-mediated vasoconstriction, elevated levels of the ET(B) receptor mRNA and protein expressions, and activation of ERK1/2 and p38 MAPK. Blockage of ERK1/2 and p38 MAPK signal pathways using MEK1/2 inhibitors (PD98059 and U0126) or p38 inhibitors (SB203580 and SB239063) significantly abolished the LDL-induced upregulation of vasoconstrictive ET(B) receptor expression. Actinomycin D (general transcriptional inhibitor) almost completely inhibited the LDL effects. In conclusion, LDL induces upregulation of vasoconstrictive ET(B) receptor expression through activation of ERK1/2 and p38 MAPK signal pathway-dependent transcriptional mechanisms.

KEYWORDS:

Actinomycin D (PubChem CID: 2019); Endothelin receptor; Ischemia; LDL; MAPK; PD98059 (PubChem CID: 4713); SB203580 (PubChem CID: 176155); SB239063 (PubChem CID: 5166); Sarafotoxin 6c (PubChem CID: 16132429); U0126 (PubChem CID: 3006531); Vasoconstriction

PMID:
24315856
DOI:
10.1016/j.vph.2013.11.004
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center